MGTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
MeiraGTx Holdings plc
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$9.45+0.17 (+1.83%)
Close on Oct 19, 2026
- Market cap
- $886.46M
- P/E (TTM)
- 13.3
- Dividend yield
- –
Share price
+$1.70 (+21.94%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
MeiraGTx Holdings plc grew revenue 948.3% to $397.50M over the twelve months to Jun 30, 2026. Free cash flow was $10.47M.
Revenue
$397.50M
+948.3% vs. a year earlier
Operating income
$184.03M
TTM Q2 2026
Free cash flow
$10.47M
TTM Q2 2026
EPS, diluted
$0.71
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $886.46M
- P/E ratio
- 13.3
- Price to sales
- 2.23
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- 1.18%
Fundamentals
- Revenue
- $397.50M
- Net income
- $78.98M
- EPS, diluted
- $0.71
- Free cash flow
- $10.47M
- Diluted shares
- 94M
Ten years at a glance
Fiscal years 2016 to 2025 and trailing twelve months, USD
Revenue
$397.50M+948.3% YoY
Operating income
$184.03M
Net income
$78.98M
EPS, diluted
$0.71
Free cash flow
$10.47M
Reported periodTrailing twelve months